Dianthus Therapeutics (DNTH) vs Indivior Pharmaceuticals (INDV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Indivior Pharmaceuticals (INDV) over the past year, gaining 144.6% versus a gain of 52.3%. Over five years, INDV leads with a +127.9% price change compared with -21.2% for DNTH. Dianthus Therapeutics is the larger company by market cap ($4.75 billion vs $4.26 billion), about 1.1 times the size, while Indivior Pharmaceuticals is growing revenue faster (+4.3% vs -67.3%).
Indivior Pharmaceuticals converts more of its revenue into profit, with a net margin of 16.9% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | INDV |
|---|---|---|
| Share price | $84.88 | $36.13 |
| Market cap | $4.75B | $4.26B |
| 1-day change | -0.61% | +0.64% |
| YTD return | +105.97% | +0.70% |
| 1-year return | +144.61% | +52.32% |
| 5-year return | -21.17% | +127.95% |
| P/E ratio (TTM) | — | 12.95 |
| Forward P/E | — | 7.40 |
| EPS (TTM) | $-4.24 | $2.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $1.24B |
| Revenue growth (YoY) | -67.35% | +4.29% |
| Net income (latest FY) | $-162.34M | $210.00M |
| Gross margin | — | 80.23% |
| Operating margin | -8739.34% | 21.15% |
| Net margin | -7973.33% | 16.95% |
| 52-week high | $117.88 | $42.81 |
| 52-week low | $32.22 | $22.95 |
| Distance from 52-week high | -27.99% | -15.60% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +65.88% | +35.62% |
| Average volume | 825.33K | 2.07M |
| Shares outstanding | 55.93M | 118.03M |
| Employees | 92 | 827 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed INDV by 92.3 percentage points over the past year.
- Indivior Pharmaceuticals is more profitable, keeping 16.9 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- Indivior Pharmaceuticals grew revenue faster in its latest fiscal year (+4.29% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
DNTH vs INDV FAQ
Which is bigger, Dianthus Therapeutics or Indivior Pharmaceuticals?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.75B compared with $4.26B for Indivior Pharmaceuticals (INDV).
Which stock has performed better over the past year, DNTH or INDV?
DNTH returned +144.61% over the past 12 months, compared with +52.32% for INDV (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Indivior Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.